PUMA BIOTECHNOLOGY, INC.: AMERICAN CENTURY INVESTMENT MANAGEMENT INC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
American Century Investment Management Inc. disclosed a stake exceeding 5% in Puma Biotechnology Inc. via a Schedule 13G filing with the SEC (accession 0000052388-26-000503). The exact share count and percentage were not specified in the filing headline. The disclosure signals a significant institutional position in the clinical-stage oncology company, whose sole marketed product is Nerlynx (neratinib) for HER2-positive breast cancer. Investors will watch for the full 13G details, including share totals and any passive-investor intent, plus Puma's upcoming quarterly results and Nerlynx revenue trends.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Puma Biotechnology, Inc., American Century Investment Management Inc